Real stories. Real impact. A better world.
GOOD NEWS DAILY
AllAnimalsCommunityEconomyEnvironmentHealthHumanityInnovationScienceWeekly Recap

Diabetes drug empagliflozin cut inflammatory blood cell clumps within two weeks in small Vanderbilt study

In a Vanderbilt pilot study of 16 women with obesity and prediabetes, empagliflozin reduced blood cell clumps linked to heart disease within two weeks. Women on a low-calorie diet did not show the drop. A larger placebo-controlled trial is now enrolling.

By , Editor

· United States · 3 min read

Source: Vanderbilt Health News ↗
Share
White tablets spilling out of an open medicine bottle onto a yellow surface
White tablets spilling out of an open medicine bottle onto a yellow surface. Photo: HeungSoon (Pixabay)

A widely used diabetes drug reduced clumps of inflammatory cells in the blood within two weeks in a small study of 16 women with obesity and prediabetes, Vanderbilt Health said on 5 October. The drug, empagliflozin, belongs to a class called SGLT2 inhibitors. The pilot study, led by Mona Mashayekhi of Vanderbilt's Division of Diabetes, Endocrinology and Metabolism, was published in Circulation, a journal of the American Heart Association.

The cells in question are thought to feed the inflammation that damages blood vessels. The study is small and was not placebo-controlled, so it shows a biological effect rather than a health benefit for patients.

Clumps of platelets and immune cells fell only in the drug group

SGLT2 inhibitors make the kidneys pass more sugar into the urine, which lowers blood glucose and body weight. The Vanderbilt team wanted to know whether the drug also changes the immune system, something earlier animal studies had hinted at.

The 16 women took empagliflozin for three months, with tests at the start, after two weeks and after three months. The researchers compared them with a separate group of women who followed a low-calorie diet for three months.

Using genetic sequencing and cell imaging, they tracked monocyte-platelet aggregates. These form when platelets, the cells that help blood clot, stick to monocytes, a type of white blood cell. The aggregates are thought to contribute to vascular inflammation and heart disease. In the drug group they dropped significantly within two weeks, and the drop was larger by week 12. The diet group showed no such reduction, which the researchers read as a sign that the effect is not simply the result of weight loss.

The women's monocytes also changed how they used energy, moving away from a highly inflammatory state toward a more stable one. The university calls this "metabolic reprogramming."

“This study provides the first direct evidence of SGLT2 inhibitors altering human immune cells which may potentially reduce cardiovascular risk.” — Mona Mashayekhi, MD, PhD, assistant professor of medicine, Vanderbilt Health

Mashayekhi said earlier animal studies had suggested these medications might be modulating the immune system, "but that hadn't really been shown in humans."

A possible explanation for heart benefits seen in large trials

Empagliflozin's effect on the heart is already well documented. In the EMPA-REG OUTCOME trial of 7,020 people with type 2 diabetes at high cardiovascular risk, published in the New England Journal of Medicine in 2015, patients on the drug had a 38% lower relative risk of death from cardiovascular causes and a 35% lower relative risk of hospitalization for heart failure than those on placebo. Death from any cause fell by 32%.

That trial did not explain why. Mashayekhi said understanding how these drugs reduce inflammation linked to obesity, heart disease and kidney disease could help doctors "identify the best patient for this treatment or discover other drug targets in that pathway."

A 74-person placebo-controlled trial is enrolling

Mashayekhi's group has started a randomized, placebo-controlled trial at Vanderbilt with a planned 74 participants with obesity and metabolic syndrome. It will track the same immune measures over three months and will also collect fat tissue to study inflammation linked to obesity. Common medicines may matter for people with diabetes in other ways too. A large Danish study linked early statin use after a type 2 diabetes diagnosis to a lower dementia risk.

The pilot was funded in part by the U.S. National Institutes of Health. It did not measure heart attacks, strokes or other clinical outcomes, and it included only women.

Not medical advice. This article reports on research and health programs for general information. Results from early studies often change in larger trials. Talk to a doctor before making decisions about your own health or treatment.

Sources

How we choose and verify sources: editorial policy.

More stories: Medical research progress (27) →

Your weekly dose of good news

The 5 biggest positive stories of the week, straight to your inbox. Free, no noise.

Plastic anatomical models of the human heart on a table
Health

USF Lab Is Building Living Heart Valves That Could Grow With Children